OakChart

Roivant Sciences Ltd

ROIVHealthcare·Biotechnology·United Kingdom·Large·NASD·Nov 11 • 10:57 AM ET

41.46+0.27 (0.66%)
2026-11-11 16:58 CET
Market cap
29,752.48 USD m
Revenue, TTM
41.08 USD m
Net income, TTM
-360.12 USD m
Free cash flow, TTM
-33.34 USD m
EPS diluted, TTM
-0.56
P/E
-
Compare

Price

ROIV against its 20, 50 and 200-day averages
2050200beat
20.0025.0030.0035.0040.0019.7M39.4MMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26ROIVclose 41.4620-day 37.0550-day 37.08200-day 32.1341.4652w high52w low

2.4% under the 52-week high of 42.50 on 8 Sep 2026. 52-week low 19.96 on 2 Dec 2025. Last 15 sessions, 17.6% high to low

Profile

ROIV
52-week range, 95% of the way up
19.9642.50

Roivant Sciences Ltd. engages in the biopharmaceutical business, which engages in the development of transformative medicine. Its product portfolio includes Vtama, Batoclimab, Brepocitinib, Namilumab, and RVT-2001, which aims to treat psoriasis, atopic dermatitis, thyroid eye disease, and other illnesses. The company was founded by Vivek Ramaswamy on April 7, 2014 and is headquartered in London, the United Kingdom.

IndexRUI
Employees721
IPODec 08, 2020
Beta1.19
ATR, 14d1.54
Rel volume0.68
Short float8.68%
Insider own27.42%
Inst own77.46%

Snapshot

6 groups

Valuation

IndexRUI
Market Cap30.04B
Enterprise Value26.51B
Income-360.12M
Sales41.08M
Book/sh5.56
Cash/sh5.81
Dividend Est.-
Dividend TTM-
Dividend Ex-Date-
Dividend Gr. 3/5Y- -
Payout-
Employees721
IPODec 08, 2020

Ratios

P/E-
Forward P/E-
PEG-
P/S731.26
P/B7.46
P/C7.14
P/FCF-
EV/EBITDA-
EV/Sales645.44
Quick Ratio15.56
Current Ratio15.56
Debt/Eq0.03
LT Debt/Eq0.02
Option/ShortYes / Yes

Earnings

EPS (ttm)-0.56
EPS next Y-1.14
EPS next Q-0.30
EPS this Y-118.03%
EPS next Y3.07%
EPS next 5Y0.09%
EPS past 3/5Y32.67% 34.68%
Sales past 3/5Y-48.73% -19.07%
EPS Y/Y TTM9.46%
Sales Y/Y TTM102.09%
EPS Q/Q-72.11%
Sales Q/Q2135.58%
EarningsNov 09 BMO
EPS/Sales Surpr.26.35% 709.97%

Ownership

Insider Own27.42%
Insider Trans-3.50%
Inst Own77.46%
Inst Trans2.79%
ROA-7.17%
ROE-8.59%
ROIC-8.76%
Gross Margin82.51%
Oper. Margin-3233.98%
Profit Margin-876.58%
SMA2011.90%
SMA5011.82%
SMA20029.04%
Trades-

Technical

Shs Outstand723.69M
Shs Float524.29M
Short Float8.68%
Short Ratio5.72
Short Interest45.51M
52W High42.50 -2.45%
52W Low19.96 107.72%
Volatility5.80% 4.11%
ATR (14)1.54
RSI (14)67.05
Beta1.19
Rel Volume0.68
Avg Volume7.96M
Volume1,408,758

Performance

Perf Week8.45%
Perf Month24.32%
Perf Quarter14.28%
Perf Half Y41.89%
Perf YTD91.06%
Perf Year98.37%
Perf 3Y370.60%
Perf 5Y430.18%
Perf 10Y-
Recom1.40
Target Price50.64
Prev Close41.19
Price41.46
Change %0.66%

Analyst ratings

latest 10 of 19
DateActionAnalystRating changeTargetImplied
Oct 12, 2026DowngradeWWolfe ResearchOutperform → Peer Perform
Sep 17, 2026InitiatedSStifelBuy$51+23.0%
Mar 20, 2026InitiatedBBernsteinOutperform$35-15.6%
Sep 02, 2025InitiatedCCitigroupBuy$16-61.4%
Jul 10, 2025ResumedGGoldmanBuy$19-54.2%
Feb 15, 2024InitiatedWWolfe ResearchOutperform$17-59.0%
Jan 05, 2024InitiatedPPiper SandlerOverweight$20-51.8%
Dec 12, 2023InitiatedDDeutsche BankBuy$14-66.2%
Oct 17, 2023InitiatedGGuggenheimBuy$17-59.0%
Jun 08, 2023InitiatedBBofA SecuritiesNeutral$10.50-74.7%

Peers

Mkt cap
TickerCompanyMkt cap
ARGXArgen X SE ADR60.88B
INCYIncyte Corp24.55B
BBIOBridgeBio Pharma Inc15.38B
ALNYAlnylam Pharmaceuticals Inc20.95B
ABVXAbivax ADR8.09B
INSMInsmed Inc26.13B
REGNRegeneron Pharmaceuticals Inc94.28B
MRNAModerna Inc99.75B
VRTXVertex Pharmaceuticals Inc136.49B
IONSIonis Pharmaceuticals Inc4.79B

Insider trading

latest 14 of 100
InsiderRelationshipDateTransactionCostSharesValueTotal heldForm
Venker EricOfficerNov 10 '26Proposed Sale40.53187,9437,617,817Nov 10 04:36 PM
MAYUKH SUKHATMEOfficerNov 10 '26Proposed Sale41.00173,7257,122,725Nov 10 04:28 PM
MATTHEW ADAM GLINEOfficerNov 10 '26Proposed Sale41.00164,1366,729,576Nov 10 04:25 PM
FRANK M TORTIOfficerNov 10 '26Proposed Sale41.081,234,96450,732,321Nov 10 04:23 PM
RICHARD PULIKOfficerNov 10 '26Proposed Sale41.20125,0005,150,575Nov 10 04:23 PM
Venker EricPresident & Immunovant CEONov 03 '26Sale36.31200,0007,262,000999,154Nov 05 06:11 PM
Venker EricOfficerNov 03 '26Proposed Sale36.31200,0007,262,568Nov 03 04:29 PM
Venker EricPresident & Immunovant CEOOct 28 '26Sale36.59200,0007,318,0001,199,154Oct 30 06:29 PM
Venker EricOfficerOct 28 '26Proposed Sale36.59200,0007,317,764Oct 28 04:35 PM
Venker EricPresident & Immunovant CEOOct 20 '26Sale35.11200,0007,022,6681,399,154Oct 22 06:44 PM
Venker EricOfficerOct 20 '26Proposed Sale35.12200,0007,023,513Oct 20 04:44 PM
Epperly Melissa B,DirectorOct 01 '26Option Exercise4.4617,75079,16532,704Oct 05 06:05 PM
Epperly Melissa B,DirectorOct 01 '26Sale36.1017,750640,86114,954Oct 05 06:05 PM
Venker EricPresident & Immunovant CEOSep 30 '26Option Exercise3.85200,000770,0001,799,154Oct 02 05:37 PM

Held by

AUM
TickerCompanyAUM
IJHiShares Core S&P Mid-Cap ETFAUM: 124.48B
VTIVanguard Morningstar Total Stock Market ETFAUM: 687.42B
VBVanguard Morningstar Small-Cap ETFAUM: 79.59B
XMMOInvesco S&P MidCap Momentum ETFAUM: 6.37B
VBKVanguard Morningstar Small-Cap Growth ETFAUM: 22.34B
VXFVanguard Extended Market Index ETFAUM: 30.47B
MDYState Street SPDR S&P MIDCAP 400 ETF TrustAUM: 26.22B
IBBiShares Biotechnology ETFAUM: 11.36B
XBIState Street SPDR S&P Biotech ETFAUM: 10.50B
SPMDState Street SPDR Portfolio S&P 400TM Mid Cap ETFAUM: 18.90B

News

latest 14 of 206
  • Priovant Announces Publication of Phase 2 BEACON Results for Brepocitinib in Cutaneous Sarcoidosis in JAMA Dermatology (GlobeNewswire)
  • Roivant Beats As LISRAYA Launch Lands At $31 Million, But Stocking And An Unsettled RA Path Complicate A Breakout Quarter (Earnings Whispers)
  • Roivant Reports Financial Results for the Second Quarter Ended September 30, 2026, and Provides Business Update (GlobeNewswire)
  • Roivant's First Post-Launch Report Puts Brepacitinib And A Crowded Catalyst Calendar To The Test (Earnings Whispers)
  • Roivant Social Ventures Announced Support of No Patient Left Behind with Six-Figure Organizational Legacy Gift (GlobeNewswire)
  • Loading…
  • Roivant Sciences stock surges on positive uveitis trial data (Investing.com) +5.38%
  • Roivant to Report Financial Results for the Second Quarter Ended September 30, 2026, and Provide Business Update on Monday, November 9, 2026 (GlobeNewswire)
  • Roivant and Priovant Announce Positive Results in CLARITY-1 and CLARITY-2 Phase 3 Trials for Brepocitinib in Non-Infectious Uveitis (NIU) (GlobeNewswire)
  • IMVT, ROIV Stocks Slide As Argenx Sjögrens Trial Failure Hits Drug Class (Stocktwits)
  • Roivant's Immunovant Stops IMVT-1402 Development in Cutaneous Lupus After Trial Miss (InvestorsHub)
  • Roivant Announces Topline Results from Proof-of-Concept Study of IMVT-1402 in Cutaneous Lupus Erythematosus (GlobeNewswire)
  • Podcast: key readouts from ESC and ERS (Pharmaceutical Technology)
  • Why Did DELL, ROIV, SHEL Stocks Surge To 52-Week Highs Today? (Stocktwits) +18.75%

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
2026Q22026-11-09-0.270-0.367-0.27035.124.3411
2026Q12026-08-06-0.335-0.300-0.2631.442.068
2025Q42026-05-200.279-0.2890.3732.523.4112
2025Q32026-02-06-0.170-0.300-0.3822.005.089
2025Q22025-11-10-0.202-0.320-0.1671.575.6210
2025Q12025-08-11-0.252-0.250-0.3282.177.308
2024Q42025-05-29-0.290-0.264-0.2927.5754.077
2024Q32025-02-10-0.203-0.2530.2349.025.007
2024Q22024-11-12-0.285-0.247-0.3134.4845.9210
2024Q12024-08-080.120-0.2430.12255.1330.729
2023Q42024-05-30-0.190-0.264-0.18828.9331.0111
2023Q32024-02-136.030-0.3096.03537.1431.7710
2023Q22023-11-13-0.263-0.288-0.39537.1027.1110
2023Q12023-08-14-0.227-0.283-0.38421.6224.499
2022Q42023-06-28-0.219-0.361-0.04527.3818.179
2022Q32023-02-13-0.414-0.395-0.49417.0514.788

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
2021FY-1.171-1.180-1.26255.2952.87
2022FY-1.151-1.588-1.41661.2852.28
2023FY5.2305.2215.233124.8181.74
2024FY-0.240-0.521-0.23729.05141.38
2025FY-0.540-1.121-0.5408.269.09
2026FY--1.186--139.46
2027FY--1.141--615.39
2028FY--0.548--1,600
2029FY-1.004--3,272
2030FY-2.856--5,612

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
2026Q3S2026-11-09119040.911.5066.00
2026Q3S2026-11-04112214.551.5027.00
2026Q3S2026-10-28111314.381.5027.00
2026Q3S2026-10-21111212.310.0027.00
2026Q3S2026-10-20111312.310.0027.00
2026Q3S2026-09-16112412.310.0027.00
2026Q3S2026-09-15113312.340.0027.00
2026Q3S2026-09-11103311.870.0027.00
2026Q3S2026-09-09102411.850.0027.00
2026Q3S2026-09-08102411.860.0027.00
2026Q3S2026-09-07102411.850.0027.00
2026Q3S2026-09-04102411.850.0027.00
2026Q3S2026-08-28102411.850.0027.00
2026Q3S2026-08-27102312.930.0037.50

Estimate history

EPS, annual-4.8385.213-3.634-1.262-1.4165.233-0.237-0.432-0.5589
Period20182019202020212022202320242025TTM
EPS, quarterly-0.3130.234-0.292-0.328-0.167-0.3820.373-0.263-0.287
PeriodQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26
Sales, annual2.32467.68923.79555.28661.2832.71329.0538.2641.08
Period20182019202020212022202320242025TTM
Sales, quarterly4.4759.0187.572.171.5711.9992.521.44235.121
PeriodQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26
Shares, annual215.353215.353222.67694.976760.143806.678695.938720.352723.687
Period20182019202020212022202320242025MRQ
Shares, quarterly733.328719.632695.938682.23689.697709.689720.352722.668723.687
PeriodQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26

Income statement, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2020FY2019FY
Total Revenue41.088.2629.0532.7161.2855.2923.800.0067.69
Cost of Goods Sold Incl. D&A7.184.638.2412.1832.088.972.060.001.13
Gross Profit33.903.6320.8120.5429.2046.3221.740.0066.56
Selling, General and Administrative Excl. Other1,362.481,271.831,134.49845.461,106.771,258.071,092.640.37598.98
Research and Development712.09681.81550.41439.91525.22483.04832.76-263.22
Other Operating Expense0.000.000.000.000.000.000.000.090.00
Operating Income-1,328.58-1,268.20-1,113.68-824.93-1,077.57-1,211.75-1,070.90-0.45-532.42
Interest Expense0.000.000.000.0027.977.042.81-7.68
Unusual Expense-838.81-810.48-70.94121.26196.56223.83-65.69-0.01122.28
Net Income Before Taxes-297.18-264.58-681.594,567.86-1,224.83-923.75-898.55-0.37-560.99
Income Taxes104.36133.3348.1721.505.190.371.690.027.12
Consolidated Net Income-401.54-397.91-729.764,546.35-1,230.02-924.12-900.23-0.39-568.11
Net Income From Continuing Operations-360.12-299.77-545.014,664.07-1,123.59-845.26-809.23-0.39-519.39
Net Income-360.12-299.77-171.984,348.93-1,009.03-845.26-809.23-0.391,122.73
EPS (Recurring)-1.31-1.25-0.315.34-1.22-1.03-3.84-0.015.61
EPS (Basic, Before Extraordinaries)-0.50-0.43-0.245.55-1.42-1.26-3.63-0.015.21
EPS (Diluted)-0.56-0.43-0.245.23-1.42-1.26-3.63-0.015.21
EBITDA-1,326.05-1,264.86-1,106.35-814.35-1,051.15---0.45-
Non-Operating Income (Expense)192.59193.15361.155,514.0577.27518.87109.470.08101.41
Other After Tax Adjustments0.000.000.000.000.000.000.000.000.00
Stock Option Compensation Expense289.85273.47228.33157.71172.05412.4262.02-49.46
Price To Earnings Ratio---2.02-----
Price To Sales Ratio643.372,326.88251.93267.7685.8459.84---
Gross Margin82.5143.9171.6362.7747.6583.7891.36-98.33
Operating Margin-3,233.98-15,353.55-3,833.27-2,521.71-1,758.44-2,191.78-4,500.52--786.58
Net Margin-876.58-3,629.19-591.9613,294.18-1,646.59-1,528.89-3,400.86-1,658.66
Shares Outstanding723.69720.35695.94806.68760.14694.98222.6751.34215.35
Market Capitalization29,752.4829,752.487,199.718,493.625,597.193,418.843,280.42--

Income statement, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q12024Q42024Q3
Total Revenue35.121.442.522.001.572.177.579.02
Cost of Goods Sold Incl. D&A3.950.880.961.391.031.251.592.20
Gross Profit31.170.561.560.610.540.925.986.82
Selling, General and Administrative Excl. Other299.22366.94356.56339.76306.77285.84290.95281.20
Research and Development145.75202.02198.94165.38164.57152.92144.79141.59
Other Operating Expense0.000.000.000.000.000.000.000.00
Operating Income-268.05-366.38-355.00-339.15-306.23-284.92-284.96-274.38
Interest Expense0.000.000.000.000.000.000.000.00
Unusual Expense-60.29-37.03-744.312.82-107.5421.45-27.0219.17
Net Income Before Taxes-166.34-294.56454.10-290.37-159.04-269.26-203.05-234.51
Income Taxes-13.37-3.9698.3523.337.004.6549.32-25.57
Consolidated Net Income-152.97-290.61355.74-313.70-166.04-273.91-252.38-208.94
Net Income From Continuing Operations-207.38-189.84302.99-265.89-113.52-223.35-206.47-157.64
Net Income-207.38-189.84302.99-265.89-113.52-223.35-206.47169.38
EPS (Recurring)-0.35-0.30-0.27-0.38-0.28-0.31-0.320.25
EPS (Basic, Before Extraordinaries)-0.29-0.260.43-0.38-0.17-0.33-0.290.23
EPS (Diluted)-0.29-0.260.37-0.38-0.17-0.33-0.290.23
EBITDA-267.44-365.79-354.36-338.46-305.31-283.82-283.58-272.44
Non-Operating Income (Expense)41.4134.7964.7851.6139.6537.1154.8959.03
Other After Tax Adjustments0.000.000.000.000.000.000.000.00
Stock Option Compensation Expense62.6465.8492.7468.6364.6464.9265.9562.47
Price To Earnings Ratio-------2.09
Price To Sales Ratio643.373,386.662,724.011,136.13506.80330.0093.6687.64
Gross Margin88.7538.7061.9830.4234.3142.3079.0275.58
Operating Margin-763.22-25,408.11-14,087.10-16,966.13-19,492.87-13,130.05-3,764.40-3,042.59
Net Margin-590.48-13,164.8412,023.57-13,301.20-7,225.91-10,292.86-2,727.541,878.25
Shares Outstanding723.69722.67720.35709.69689.70682.23695.94719.63
Market Capitalization29,752.4825,454.9719,824.9215,092.1810,332.007,661.417,199.718,611.65

Balance sheet, annual

Currency USD, millions
Metric2025FY2024FY2023FY2022FY2021FY2020FY2020FY2019FY2018FY
Cash & Short Term Investments4,295.694,889.256,498.021,681.822,064.302,132.741.702,185.48849.55
Short Term Receivables789.840.000.0032.730.0013.830.0015.2810.97
Inventories0.000.000.002.760.000.000.000.000.00
Other Current Assets81.86110.81233.8181.2782.2240.420.2818.48324.95
Total Current Assets5,167.385,000.066,731.831,798.592,146.522,186.991.982,219.241,185.48
Net Property, Plant & Equipment92.40101.0859.3292.3486.9577.030.0073.9311.11
Total Investments and Advances415.88310.83255.92314.61335.56298.47410.80177.22169.80
Long-Term Note Receivable-----100.00---
Intangible Assets--137.84144.88--0.00--
Deferred Tax Assets19.36-----0.00--
Other Assets33.0224.97175.4139.1916.0927.200.006.6621.43
Total Assets5,728.055,436.947,222.482,389.602,585.132,689.69412.782,477.051,387.81
Short Term Debt Incl. Current Port. of LT Debt11.159.848.9754.5011.4012.310.007.8421.18
Accounts Payable18.0023.6914.0337.8334.5820.550.0010.316.23
Income Tax Payable45.690.429.770.54-0.210.021.500.41
Other Current Liabilities206.41115.46233.99179.57138.39185.890.5472.48183.44
Total Current Liabilities281.24149.41266.76272.45184.37218.960.5592.12211.27
Long Term Debt96.2990.3345.02432.56272.49232.660.00173.04121.99
Provision for Risks Charges0.000.000.000.000.000.000.000.000.00
Deferred Tax Liabilities19.36-----0.00--
Other Liabilities38.7410.00462.1877.0066.8376.0614.38103.19117.25
Total Liabilities435.63249.74773.95782.02523.70527.6914.93368.36450.51
Non-Equity Reserves0.000.000.000.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.000.000.000.00
Common Equity4,527.374,687.605,968.581,157.771,656.941,897.79397.852,032.16716.95
Total Shareholders Equity4,527.374,687.605,968.581,157.771,656.941,897.79397.852,032.16716.95
Accumulated Minority Interest765.04499.59479.95449.82404.49264.220.0076.53220.35
Total Equity5,292.415,187.206,448.531,607.592,061.432,162.01397.852,108.70937.30
Total Liabilities & Stockholders Equity5,728.055,436.947,222.482,389.602,585.132,689.69412.782,477.051,387.81
Book Value Per Share6.286.747.401.522.388.527.759.443.33
Tangible Book Value Per Share6.286.747.401.332.388.527.759.443.33
Full-Time Employees7217509089048636202--
Price to Book Ratio7.411.401.394.852.071.76---
Return on Assets-5.37-8.6197.05-45.17-32.05-31.32--26.88-
Return on Equity-6.51-10.23130.90-79.84-47.56-41.18--37.79-
Return on Invested Capital-6.48-3.6072.32-63.45-43.81-37.98-0.1054.44-124.20
Quick Ratio18.3733.4725.246.5911.649.993.5824.095.61
Current Ratio18.3733.4725.246.6011.649.993.5824.095.61

Cash flow, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2020FY2019FY
Net Income-385.77-397.91-356.734,231.21-1,115.46-924.12-900.23-0.391,010.32
Depreciation2.533.357.3310.5826.42----
Other Funds (Non Cash)244.06266.01-413.00-5,026.09239.30230.67275.87-0.09-1,787.44
Funds from Operations-139.18-128.55-762.40-784.30-849.74-693.45-624.36-0.47-777.13
Extraordinary Item0.000.000.000.000.000.000.000.000.00
Changes in Working Capital102.79-621.80-77.0519.046.3415.7271.940.2215.30
Income Taxes Payable-85.05-----0.02-
Cash from Operating Activities-36.39-750.35-839.45-765.27-843.39-677.73-552.42-0.25-761.83
Capital Expenditures3.05-8.21-4.60-1.38-12.69-17.44-5.810.00-4.92
Net Assets From Acquisitions-4.42-4.42-31.22-84.48-6.710.000.000.00-0.50
Sale of Fixed Assets and Businesses20.880.00260.5947.500.000.000.000.001,772.19
Purchase or Sale of Investments-229.99-1,488.56-1,991.135,233.400.00320.17-28.25-410.72-51.94
Purchase of Investments-3,136.23-4,795.85-4,061.520.000.000.00-28.25-410.72-68.38
Sale Or Maturity of Investments2,906.243,307.302,070.395,233.400.00320.170.000.0016.44
Other Uses-1.610.000.000.00-140.140.00-19.090.00-20.05
Other Sources818.85818.850.088.59115.260.5621.440.000.00
Cash from Investing Activities606.76-682.33-1,766.295,203.62-44.27303.30-31.70-410.721,694.79
Cash Dividends Paid0.000.000.00-6.000.000.000.000.000.00
Change in Capital Stock73.65143.61-1,129.83493.82382.84313.42456.55412.13165.75
Repurchase of Common Pref Stock-392.41-319.50-1,293.230.000.000.00-0.110.00-1,188.46
Sale of Common Pref Stock466.06463.11163.41493.82382.84313.42456.66412.131,354.21
Proceedsfrom Stock Options193.47193.60112.78438.56379.71313.42455.76412.131,352.80
Issuance or Reduction of Debt, Net0.000.00-52.75-30.70127.50-5.490.000.00-32.06
Change in Long Term Debt0.000.00-52.75-30.70127.50-5.490.000.00-32.06
Issuance of Long Term Debt0.000.000.000.00157.6516.100.000.000.00
Reduction of Long Term Debt0.000.00-52.75-30.70-30.14-21.590.000.00-32.06
Net Financing Active Other Cash Flow-244.96-9.37-37.22-37.76-10.88-1.150.000.5383.48
Other Financing Activities Uses-284.21-48.62-37.22-37.76-10.88-1.150.000.00-0.30
Cash from Financing Activities-171.31134.24-1,219.79419.36499.46306.79456.55412.66217.16
Exchange Rate Effect3.363.770.750.626.28----
Net Change in Cash402.42-1,294.68-3,824.794,858.34-381.92-67.64-127.581.701,150.12
Free Cash Flow-33.34-758.56-844.05-766.65-856.08-695.16-558.23-0.25-766.75
Preferred Dividends (Cash Flow)-0.000.000.000.000.000.000.00-
Deferred Taxes & Investment Tax Credit-0.000.000.000.000.000.000.000.00

Balance sheet, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q1
Cash & Short Term Investments4,207.593,846.284,295.694,532.594,388.094,505.41
Short Term Receivables21.60793.23789.840.000.000.00
Inventories0.000.000.000.000.000.00
Other Current Assets126.36102.5881.86127.30123.55110.34
Total Current Assets4,355.544,742.085,167.384,659.894,511.654,615.75
Net Property, Plant & Equipment88.2690.2192.4097.01110.80101.94
Total Investments and Advances512.23452.51415.88441.80420.21291.71
Deferred Tax Assets--19.36---
Other Assets19.7921.6933.0226.6719.9423.20
Total Assets4,975.825,306.495,728.055,225.375,062.605,032.60
Short Term Debt Incl. Current Port. of LT Debt13.7812.3811.1510.449.009.40
Accounts Payable11.3025.0818.0013.2915.0611.55
Income Tax Payable59.0874.1845.697.17--
Other Current Liabilities195.75171.95206.41121.07109.7992.91
Total Current Liabilities279.91283.60281.24151.96133.86113.87
Long Term Debt92.7994.7796.2998.5089.8490.29
Provision for Risks Charges0.000.000.000.000.000.00
Deferred Tax Liabilities--19.36---
Other Liabilities7.406.2538.740.6833.4412.54
Total Liabilities380.10384.62435.63251.14257.14216.70
Non-Equity Reserves0.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.00
Common Equity4,020.324,231.274,527.374,269.264,362.334,345.63
Total Shareholders Equity4,020.324,231.274,527.374,269.264,362.334,345.63
Accumulated Minority Interest575.40690.60765.04704.97443.13470.27
Total Equity4,595.724,921.875,292.414,974.224,805.464,815.91
Total Liabilities & Stockholders Equity4,975.825,306.495,728.055,225.375,062.605,032.60
Book Value Per Share5.565.866.286.026.326.37
Tangible Book Value Per Share5.565.866.286.026.326.37
Full-Time Employees--721---
Price to Book Ratio7.415.634.603.432.381.67
Return on Assets-7.17-5.15-5.37-14.69-12.44-13.44
Return on Equity-8.59-6.21-6.51-17.11-14.73-15.84
Return on Invested Capital-5.04-4.396.55-6.09-2.55-5.04
Quick Ratio15.5616.7218.3730.6633.7040.54
Current Ratio15.5616.7218.3730.6633.7040.54

Cash flow, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q1
Net Income-137.21-290.61355.74-313.70-166.04-273.91
Depreciation0.600.600.640.690.921.10
Other Funds (Non Cash)3.8452.2080.88107.15-27.62105.60
Funds from Operations-132.77-237.81437.26-205.86-192.74-167.22
Extraordinary Item0.000.000.000.000.000.00
Changes in Working Capital727.19-32.70-601.089.377.08-37.17
Income Taxes Payable-15.11-10.18----
Cash from Operating Activities594.42-270.50-163.82-196.48-185.66-204.38
Capital Expenditures-0.21-0.42-1.264.93-7.85-4.04
Net Assets From Acquisitions0.000.00-4.420.000.000.00
Sale of Fixed Assets and Businesses20.880.00-39.2539.250.000.00
Purchase or Sale of Investments23.47281.68-642.20107.05128.27-1,081.68
Purchase of Investments-832.28-286.51-1,003.73-1,013.71-976.73-1,801.68
Sale Or Maturity of Investments855.75568.19361.531,120.771,105.00720.00
Other Uses-1.610.002.52-2.520.000.00
Other Sources0.000.00818.850.000.000.00
Cash from Investing Activities42.54281.26134.24148.72120.42-1,085.72
Cash Dividends Paid0.000.000.000.000.000.00
Preferred Dividends (Cash Flow)0.000.000.000.000.000.00
Change in Capital Stock-49.05-130.07-60.02312.8069.07-178.24
Repurchase of Common Pref Stock-74.47-206.73-111.210.000.00-208.29
Sale of Common Pref Stock25.4276.6551.19312.8069.0730.06
Proceedsfrom Stock Options0.000.64-1.16193.990.770.00
Issuance or Reduction of Debt, Net0.000.000.000.000.000.00
Change in Long Term Debt0.000.000.000.000.000.00
Issuance of Long Term Debt0.000.000.000.000.000.00
Reduction of Long Term Debt0.000.000.000.000.000.00
Net Financing Active Other Cash Flow-200.16-51.4430.50-23.86-6.48-9.53
Other Financing Activities Uses-200.16-51.44-8.75-23.86-6.48-9.53
Cash from Financing Activities-249.21-181.51-29.53288.9462.59-187.77
Exchange Rate Effect1.290.321.320.431.210.81
Net Change in Cash389.04-170.44-57.79241.61-1.45-1,477.05
Free Cash Flow594.21-270.92-165.08-191.55-193.51-208.42

Revenue breakdown

Pharmaceutical Preparations2024: 29.05M 2025: 8.26M
United Kingdom2024: 29.05M 2025: 8.26M

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-308.68%45.5M524.3M7.60M
2026-10-157.69%40.3M524.3M7.05M
2026-09-307.50%39.3M524.1M7.03M
2026-09-156.90%36.2M524.1M6.83M
2026-08-316.40%33.5M524.1M6.10M
2026-08-145.84%30.6M524.1M6.03M
2026-07-315.65%35.2M623.1M5.78M
2026-07-157.09%36.7M517.6M6.02M
2026-06-306.42%33.2M517.6M5.93M
2026-06-156.43%33.2M517.1M5.60M
2026-05-297.02%36.2M516.3M5.95M
2026-05-155.30%27.4M516.2M5.41M
2026-04-305.44%27.1M497.5M6.13M
2026-04-155.01%24.5M488.4M5.97M
2026-03-315.10%24.9M488.4M6.38M
2026-03-134.79%23.4M488.4M6.90M
2026-02-274.80%23.5M488.4M6.99M
2026-02-134.49%22.3M495.9M7.19M
2026-01-305.32%23.3M437.5M7.25M
2026-01-155.61%24.5M437.5M7.99M

Option chain

expiry 2026-11-20
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
call15.0024.7028.1019.006.0400.000.000.957-0.1590.006
call20.0019.7023.2021.174.6570.000.000.942-0.1540.008
call21.0018.7022.400.004.5880.000.000.938-0.1520.008
call22.0017.7021.200.004.1670.000.000.934-0.1510.008
call23.0016.7020.200.003.9400.000.000.930-0.1490.009
call24.0015.8018.7010.293.2931.000.000.926-0.1470.009
call25.0014.7018.400.003.8160.000.000.920-0.1440.010
call26.0013.7017.300.003.4810.000.000.915-0.1420.010
call27.0012.8016.300.003.1900.000.000.911-0.1400.011
call28.0011.8015.405.233.0671.000.000.905-0.1370.011
call29.0010.8014.306.742.8311010.000.885-0.1580.013
call30.009.8013.305.992.6354220.000.877-0.1540.013
call31.008.8012.406.422.5341510.000.868-0.1500.014
call32.007.8011.405.002.3451.000.000.859-0.1460.015
call33.006.8010.406.002.1758.000.000.847-0.1410.015
call34.005.909.602.322.0792.000.000.836-0.1360.016
call35.004.908.203.971.73919.000.000.805-0.1480.018
call36.003.907.402.401.70948.000.000.785-0.1390.019
call37.004.106.304.731.4385,8881.000.766-0.1330.020
call38.002.005.702.851.48641.000.000.684-0.2050.023
call39.001.204.503.001.2281320.000.650-0.1950.024
call40.001.802.852.200.7669050.000.617-0.1730.025
call41.000.102.451.530.82982.000.000.567-0.1680.026
call42.000.002.401.301.00546.000.000.512-0.1690.026
call43.000.002.350.701.18719.000.000.465-0.1780.026
call44.000.002.300.001.3000.000.000.413-0.1770.025
call45.000.001.400.691.0372060.000.345-0.1430.024
call46.000.002.400.001.1510.000.000.316-0.1490.023
call47.000.001.200.001.0980.000.000.263-0.1300.021
call48.000.002.350.001.2030.000.000.247-0.1370.021
call49.000.001.500.051.4712.000.000.276-0.1700.023
call50.000.000.050.101.3718.000.000.225-0.1490.020
call55.000.002.200.001.7540.000.000.189-0.1720.018
call60.000.002.150.001.0960.000.000.020-0.0190.003
put15.000.002.150.604.7781.000.00-0.043-0.1560.006
put20.000.002.150.003.5980.000.00-0.059-0.1510.008
put21.000.000.751.553.39611.000.00-0.062-0.1490.008
put22.000.000.951.803.2127.000.00-0.066-0.1480.008
put23.000.002.200.003.0130.000.00-0.070-0.1460.009
put24.000.000.750.002.8460.000.00-0.074-0.1430.009
put25.000.000.750.002.6820.000.00-0.079-0.1420.010
put26.000.000.754.302.5171500.00-0.084-0.1400.010
put27.000.000.750.352.3352010.00-0.091-0.1360.011
put28.000.000.750.002.2040.000.00-0.095-0.1340.011
put29.000.002.250.002.2140.000.00-0.115-0.1540.013
put30.000.002.250.352.0643500.00-0.123-0.1510.013
put31.000.002.300.351.9168.000.00-0.132-0.1470.014
put32.000.002.300.401.7513.000.00-0.143-0.1410.015
put33.000.000.950.851.6256.000.00-0.153-0.1370.015
put34.000.000.951.071.4823040.00-0.165-0.1320.016
put35.000.001.250.391.4551,3160.00-0.195-0.1440.018
put36.000.001.350.631.3024.000.00-0.214-0.1360.019
put37.000.001.154.401.1364.000.00-0.241-0.1260.020
put38.000.002.452.271.5953.000.00-0.315-0.2010.023
put39.000.002.651.171.47070.000.00-0.355-0.1890.024
put40.000.002.955.001.43342.000.00-0.386-0.1670.025
put41.000.003.400.001.4070.000.00-0.438-0.1620.026
put42.000.203.800.001.3530.000.00-0.490-0.1640.026
put43.000.604.309.711.3208.000.00-0.537-0.1690.026
put44.001.404.300.001.0730.000.00-0.581-0.1700.026
put45.002.255.800.001.3710.000.00-0.660-0.1380.024
put46.003.206.700.001.4820.000.00-0.684-0.1440.023
put47.004.107.700.001.5950.000.00-0.737-0.1250.021
put48.005.308.200.001.4890.000.00-0.752-0.1320.021
put49.006.109.600.001.7610.000.00-0.765-0.1380.020
put50.007.0010.500.001.8140.000.00-0.775-0.1430.020
put55.0012.0015.500.002.2380.000.00-0.811-0.1660.018
put60.0016.9020.400.002.5450.000.00-0.832-0.1820.016

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-11-10144Filing for proposed sale of securities under Rule 144.SEC
2026-11-10144/ASEC
2026-11-10144/ASEC
2026-11-10144/ASEC
2026-11-10144Filing for proposed sale of securities under Rule 144.SEC
2026-11-10144Filing for proposed sale of securities under Rule 144.SEC
2026-11-10144Filing for proposed sale of securities under Rule 144.SEC
2026-11-10144Filing for proposed sale of securities under Rule 144.SEC
2026-11-0910-QQuarterly report pursuant to Section 13 or 15(d)2026-09-30SEC
2026-11-098-KCurrent report2026-11-09SEC
2026-11-054Statement of changes in beneficial ownership of securities2026-11-03SEC
2026-11-05SCHEDULE 13G/ASEC
2026-11-03144Filing for proposed sale of securities under Rule 144.SEC
2026-10-304Statement of changes in beneficial ownership of securities2026-10-28SEC
2026-10-28144Filing for proposed sale of securities under Rule 144.SEC
2026-10-27SCHEDULE 13G/ASEC
2026-10-274Statement of changes in beneficial ownership of securities2026-10-23SEC
2026-10-274Statement of changes in beneficial ownership of securities2026-10-23SEC
2026-10-274Statement of changes in beneficial ownership of securities2026-10-23SEC
2026-10-224Statement of changes in beneficial ownership of securities2026-10-20SEC
2026-10-218-KCurrent report2026-10-21SEC
2026-10-20144Filing for proposed sale of securities under Rule 144.SEC
2026-10-204Statement of changes in beneficial ownership of securities2026-10-16SEC
2026-10-204Statement of changes in beneficial ownership of securities2026-10-16SEC
2026-10-054Statement of changes in beneficial ownership of securities2026-10-01SEC
2026-10-05SCHEDULE 13D/ASEC
2026-10-054Statement of changes in beneficial ownership of securities2026-10-01SEC
2026-10-024Statement of changes in beneficial ownership of securities2026-09-30SEC
2026-10-024Statement of changes in beneficial ownership of securities2026-09-30SEC
2026-10-024Statement of changes in beneficial ownership of securities2026-09-30SEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-11007.26M1
2026-100014.98M3
2026-09008.52M4
2026-080043.67M7
2026-07006.99M1
2026-0600162.74M13
2026-05006.05M1
2026-040014.75M3
2026-03008.77M3
2026-0200194.30M14
2026-01004.38M1
2025-1200271.86M17
2025-1100120.90M7

Institutional holders

Manager% owned
FMR LLC11.85%
BlackRock, Inc.6.71%
MORGAN STANLEY5.92%
QVT Financial LP3.30%
VANGUARD CAPITAL MANAGEMENT LLC3.08%
VANGUARD PORTFOLIO MANAGEMENT LLC3.01%
GOLDMAN SACHS GROUP INC2.58%
STATE STREET CORP2.47%
FARALLON CAPITAL MANAGEMENT, L.L.C.1.99%
UBS Group AG1.93%

Funds

Fund% owned
Fidelity Growth Company Fund3.19%
VANGUARD TOTAL STOCK MARKET INDEX FUND2.22%
iShares Core S&P Mid-Cap ETF2.15%
VANGUARD SMALL-CAP INDEX FUND1.61%
VANGUARD SMALL-CAP GROWTH INDEX FUND0.93%
Fidelity Growth Company K6 Fund0.92%
Fidelity Series Growth Company Fund0.78%
GROWTH PORTFOLIO0.73%
Invesco S&P MidCap Momentum ETF0.72%
VANGUARD EXTENDED MARKET INDEX FUND0.72%

OakChart. ROIV. Cached 15 minutes.